Glioblastoma: From Diagnosis to Treatment скачать в хорошем качестве

Glioblastoma: From Diagnosis to Treatment

Glioblastoma, also known as GBM, represent 14.9% of all primary brain tumors, and 55.4% of all gliomas. GBM has the highest number of cases of all malignant tumor and has a median survival rate of about 15 months. Patients and family member of a GBM diagnosis have so many questions that can go unanswered. This month’s ABTA webinar focuses on this topic from a patient perspective and discusses the entire journey from the first diagnosis to treatment and prognosis. Dr. Merrell of NorthShore Neurological Institute will elaborate on innovative treatments for GBM including minimally invasive surgery and the latest clinical trials. 0:00 Introduction & Disclosures 3:17 Distribution of Primary Brain Tumors 3:51 Risk Factors 4:54 Glioma Classification 5:51 Pathologic Classification High Grade Gliomas (Grade III and IV) 6:37 Favorable Prognostic Factors 7:37 Molecular classification 9:15 IDHI (Isocitrate Dehydrogenase 1) 10:01 Symptoms suggestive of brain tumors 12:58 The multidisciplinary team 13:53 Newly Diagnosed Tumors 16:56 62 Year-old Male with Headache Surgery Done with Fluorescent Dye 17:30 Fluorescent dye surgery 20:12 Medical Management 20:29 Cerebral edema (brain swelling) 24:10 Antiepileptic Drugs 24:46 Fatigue 26:11 DVT/PE (Blood clots) 27:55 Psychosocial Management 29:19 Historical Timeline of GBM Treatment 30:37 Standard treatment after Surgery, Stupp Regimen 36:16 Standard Treatments: Recurrent 37:33 Bevacizumab (Avastin) 46:50 REACT 50:00 Immune Dysregulation 54:29 Checkpoint Inhibitors 54:58 Checkmate 143 trial 55:31 Attenuated Viral Therapies